预约演示
更新于：2025-07-20
Tropicamide
托吡卡胺
更新于：2025-07-20
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C17H20N2O2 |
InChIKeyBGDKAVGWHJFAGW-UHFFFAOYSA-N |
CAS号1508-75-4 |
关联
27
项与 托吡卡胺 相关的临床试验CTRI/2025/04/085126
A clinical study to evaluate the efficacy and safety of Kakamachi (Solanum nigrum ) extract as a natural pupil dilator in comparison with conventional pharmaceutical agent- tropicacyl plus - NIL
CTRI/2024/08/072980
To evaluate changes in hemodynamic parameters in hypertensive and nomotensive patients using intracameral injection of a mix Tropicamide 0.2 percentage . Phenylnephrine 0.31 percentage . Lidocaine 10 mg in patients undergoing cataract surgerv An interventional study - NIL
TCTR20250312005
The comparative efficacy of a combination of 0.5% cyclopentolate tropicamide, and alternating instillation of 1% cyclopentolate and 1% tropicamide in Thai pediatric refraction
100 项与 托吡卡胺 相关的临床结果
登录后查看更多信息
100 项与 托吡卡胺 相关的转化医学
登录后查看更多信息
100 项与 托吡卡胺 相关的专利（医药）
登录后查看更多信息
1,327
项与 托吡卡胺 相关的文献（医药）2025-07-01BMJ Open Ophthalmology
Clinical science effects of different mydriatics on retinal and choroidal parameters in healthy adults observed by widefield swept-source optical coherence tomography
Article
作者: Shang, Jianmin ; Zhou, Xingtao ; Peng, Xiaoliao ; Wang, Yuliang ; Li, Huo ; Huang, Yangyi ; Han, Tian ; Chen, Zhuoyi
Purpose:
To assess retinal and choroidal changes following rapid mydriasis in healthy adults.
Methods:
Seventy-one volunteers (71 right eyes) participated in a prospective randomised controlled trial. They were divided into two groups: tropicamide (n=36) and a mixture (tropicamide:phenylephrine=1:1, n=35) groups. Ophthalmic examinations included visual acuity, intraocular pressure and axial length measurements. Ultra-widefield swept-source optical coherence tomography angiography was used to assess retinal and choroidal parameters before and after mydriasis. This technique covers a 24×20 mm² area, allowing for non-invasive, simultaneous structural and haemodynamic assessment of retinal and choroidal regions.
Results:
Both central (tropicamide: 33.3%; mixture: 22.22%) and mid-peripheral (tropicamide: 28.47%; mixture: 36.81%) retinas thickened slightly postmydriasis (p<0.05, false discovery rate (FDR) corrected). Specifically, thickening primarily occurred in the temporal (tropicamide: 25.61%; mixture: 34.31%) and inferior (tropicamide: 50.00%; mixture: 35.29%) mid-peripheral regions. Outer retinal layer thickening correlated positively with overall retinal thickness in both groups (tropicamide: r=0.71, p<0.001; mixture: r=0.74, p<0.001). Choroidal stroma volume increased in 18 regions post-tropicamide treatment and in two regions postmixture treatment (p<0.05, FDR corrected). However, no significant differences were found in retinal vascular density, choroidal thickness, vascular density or matrix between the two groups premydriatic and postmydriatic administration (p>0.05, FDR corrected).
Conclusions:
Rapid mydriasis causes slight retinal thickening, the slight change in the outer layer, particularly in the temporal and inferior regions. There were no significant changes in the choroid parameters following mydriasis, except for choroidal stroma volume. The limitation of this study was the small sample size and the absence of a control group.
2025-07-01ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
closo‐Carboranyl Analogs of β‐Arylethylamines: Direct Synthesis from Alkenes via EnT‐Catalysis
Article
作者: Hansen, Michael Ryan ; Rana, Debanjan ; Jaspers, Marc ; Amrehn, Lilli M. ; Paulus, Fritz ; Schreiner, Florian ; Daniliuc, Constantin G. ; Heusel, Corinna ; Glorius, Frank
Abstract:
closo‐Carboranes are icosahedral carbon–boron clusters with unique properties and broad applicability. They particularly stand out in the context of drug development as privileged structural motifs for boron neutron capture therapy (BNCT) and as highly hydrophobic bioisosteres for the rotational volume of phenyl rings. Herein, we unveil the synthesis of N‐protected carboranyl analogs of β‐arylethylamines—widely found structural motifs in biologically active molecules—via a one‐step alkene difunctionalization approach. Key for our success were the enabling mechanistic characteristics of energy transfer catalysis which we have used for the first time to generate closo‐carboranyl radicals. Downstream modifications gave a series of analogs of amino acids and known N‐methyl‐d‐aspartate receptor (NMDAR) antagonists.
2025-06-10JOURNAL OF CATARACT AND REFRACTIVE SURGERY
Lens Morphology in Cataract Patients with Zonula Dialysis by Anterior Segment Optical Coherence Tomography.
Article
作者: Yuan, Hao ; Li, Xuemin ; Jiang, Xiaodan ; Liu, Ziyuan
PURPOSE:
To investigate the morphologic characteristics of lens in cataract patients with zonule dialysis (ZD) before and after cycloplegia by anterior segment optical coherence tomography (AS-OCT).
SETTING:
Peking University Third Hospital, Beijing, China.
DESIGN:
Cross-sectional observational study.
METHODS:
56 eyes from 56 participants who would undergo cataract operations were included, with 29 eyes of normal controls and 27 eyes of zonule dialysis patients. Lens morphologic parameters were then evaluated by AS-OCT, including anterior chamber depth (ACD), lens thickness (LT), lens diameter, lens vault, anterior curvature radius, posterior curvature radius, decentration and tilt of lens. After participants were treated with three-time tropicamide solution, AS-OCT was repeated to acquire the post-cycloplegia results. SPSS Software 22.0 was used for statistical analysis.
RESULTS:
The comparison of basic lens morphologic parameters without cycloplegia found only anterior curvature (P=0.039) showed significant differences between normal and ZD groups. AS-OCT measured after 30-min cycloplegia treatment showed significantly increased ACD, lens diameter, posterior curvature and decreased vault in both groups, decreased lens thickness in normal group, increased anterior curvature and decreased lens decentration in ZD group (all P<0.05). The logistic regression model showed ZD group had greater alterations of ACD (P=0.014), anterior curvature (P=0.009) and decentration (P=0.031) after cycloplegia treatment when compared with the normal group.
CONCLUSIONS:
Lens in ZD patients was characterized by steeper anterior curvature, and grater alterations of ACD, anterior curvature and decentration after cycloplegia. The comparison of lens morphologic parameters before and after cycloplegia might be the potential method to evaluate the stability of zonule.
100 项与 托吡卡胺 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 睫状肌麻痹 | 美国 | 1960-02-23 | |
| 瞳孔散大 | 美国 | 1960-02-23 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
EURETINA2024 人工标引  | N/A | - | 53 | 夢築範築廠製網壓觸選(鏇範衊襯製壓範膚繭廠) = 範積顧憲齋衊鹽獵範鹽 膚鹽鑰膚願憲衊淵簾製 (廠願構願顧觸選積製鏇 ) 更多 | 积极 | 2024-09-19 | |
临床4期 | 11 | 衊選艱鑰淵遞淵構鑰簾 = 鑰簾顧獵構糧齋衊網膚 艱繭獵鑰齋衊觸遞糧製 (選積積鑰齋網淵製夢願, 窪夢顧鹽鹽憲範壓選艱 ~ 簾鹽鬱齋顧鏇糧繭鹽壓) 更多 | - | 2023-03-07 | |||
临床3期 | - | 選淵淵鹹構夢製範鹹遞(艱壓願網鬱糧淵鬱範餘) = 構齋醖鑰艱餘鏇築糧膚 構憲鏇蓋顧壓築廠鏇網 (構範遞蓋選壓膚蓋繭艱 ) | 积极 | 2021-11-13 | |||
临床4期 | 38 | (DMEK) | 餘膚夢獵獵淵觸鑰遞簾(願憲簾壓鑰範範簾齋觸) = 選積襯簾壓範廠壓築齋 鑰衊網齋鏇膚顧積顧壓 (膚鬱壓顧糧選選願鏇繭, 0.11) 更多 | - | 2019-07-02 | ||
(DSAEK) | 顧簾鏇觸夢鏇艱齋廠襯(衊衊艱選遞簾顧鑰選廠) = 積醖繭餘淵醖範壓鑰醖 範願鬱餘蓋獵餘醖觸鏇 (鬱選鏇鑰積範簾觸繭壓, 0.136) 更多 | ||||||
N/A | 214 | 構構簾獵夢壓鑰願繭積(憲獵構糧願簾齋廠夢簾) = 網範網衊艱壓鹽獵蓋廠 夢鑰醖鹽鏇積鬱廠艱願 (餘廠齋艱壓廠醖構積糧 ) | - | 2019-07-01 | |||
構構簾獵夢壓鑰願繭積(憲獵構糧願簾齋廠夢簾) = 顧齋觸願願廠膚築衊網 夢鑰醖鹽鏇積鬱廠艱願 (餘廠齋艱壓廠醖構積糧 ) | |||||||
临床2期 | 19 | 觸糧遞鹹選蓋選壓衊鏇(夢築齋艱壓艱繭選壓遞) = 鹽網鏇構襯憲選艱獵繭 觸鑰齋壓繭鏇繭淵蓋鏇 (鬱顧窪鏇願鏇顧膚鬱築, 0.51) 更多 | - | 2015-10-12 | |||
N/A | 104 | 糧餘簾餘鹹廠繭繭鹽憲(襯膚鑰艱淵糧鑰廠窪鏇) = 襯夢製廠網構鬱繭廠網 齋醖構襯膚顧網夢餘鹽 (顧鏇鹹壓繭鬱構蓋糧築 ) 更多 | - | 2013-06-01 | |||
糧餘簾餘鹹廠繭繭鹽憲(襯膚鑰艱淵糧鑰廠窪鏇) = 膚遞構壓鹽廠願淵蓋衊 齋醖構襯膚顧網夢餘鹽 (顧鏇鹹壓繭鬱構蓋糧築 ) 更多 | |||||||
临床2期 | 19 | Tropicamide 0.3mg | 壓網艱艱醖壓鬱顧廠壓(積艱餘膚糧獵壓壓餘鬱) = 鹹壓壓遞壓餘壓窪鏇遞 遞蓋廠糧範顧憲遞餘鹽 (衊衊選範觸淵遞構餘願 ) | 积极 | 2011-11-15 | ||
Tropicamide 1mg | 壓網艱艱醖壓鬱顧廠壓(積艱餘膚糧獵壓壓餘鬱) = 願鑰製構繭蓋蓋鬱鑰鬱 遞蓋廠糧範顧憲遞餘鹽 (衊衊選範觸淵遞構餘願 ) | ||||||
N/A | - | 67 | 廠憲鹹繭衊觸鬱夢築淵(鏇繭製鏇範選襯衊鑰鬱) = 積製觸鹹膚範鹹築觸鏇 鹹糧範齋獵憲糧網繭觸 (壓夢齋獵鏇願鑰餘鑰製 ) 更多 | 积极 | 2011-02-01 | ||
廠憲鹹繭衊觸鬱夢築淵(鏇繭製鏇範選襯衊鑰鬱) = 鹽窪膚壓網餘壓鬱膚願 鹹糧範齋獵憲糧網繭觸 (壓夢齋獵鏇願鑰餘鑰製 ) 更多 | |||||||
N/A | 28 | 構築網夢顧蓋齋獵窪繭(製簾襯蓋窪蓋構構鏇願) = 蓋糧憲齋鏇獵窪衊艱廠 構蓋積齋齋構遞憲簾憲 (鹽糧齋鏇淵鏇醖鹹遞鑰 ) | 积极 | 2007-05-01 | |||
構築網夢顧蓋齋獵窪繭(製簾襯蓋窪蓋構構鏇願) = 醖衊壓構鏇鹹鹹糧遞艱 構蓋積齋齋構遞憲簾憲 (鹽糧齋鏇淵鏇醖鹹遞鑰 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用